Current+Research

= Current research  =

====A group of researchers led by Junji Sashihara at the National Institute of Health published a paper in 2009 examining the function of human antibodies that neutralize the Epsten-Barr virus and their possible utilization in a vaccine to EBV. The human antibody produces antibodies that disrupt EBV gp350 and gp42 (see Replication, Reproduction, and Infection). High titers of antibody are associated with neutralization of EBV. The researchers showed that a) our plasma has high titers of antibody to gp42 and b) antibody titers to EBV gp350 are more correlated more strongly than their counterparts for gp42 to neutralization of EBV. ====

====The researchers adapted the new green-fluorescent-protein-based infection neutralizing titration assay, as opposed to the traditional transformation-based method, to examine EBV, as the assay had not been used before on a human herpesvirus. This was a more efficient strategy that allows the results to be more easily replicated. ====

=
Sashihara, Junji, et al. "Human Antibody Titers to Epstein-Barr Virus (EBV) gp350 Correlate with Neutralization of Infectivity Better than Antibody Titers to EBV gp42 Using a Rapid Flow Cytometry-Based EBV Neutralization Assay." Virology. 2009 September 1; 391(2): 249-256. Web. 28 Nov. 2011. =====